In contrast, although we detected weak RBD-ACE2 inhibitory activity in the saliva from COVID-19–recovered vaccinees even prior to vaccination, these responses did not improve significantly, even after the second mRNA vaccine dose (1 × prior infection + 2 × BNT162b2) (Figure 3, E and F). The gene discussed is ACE2; the disease is COVID-19.